Treating myoclonic epilepsy in children: State-of-the-art

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 10, 2013, Pages 1355-1361

  Striano, Pasquale ^a   Belcastro, Vincenzo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

Author keywords

Antiepileptic drugs; Clinical trials; Myoclonic seizures; Myoclonus; Review; Therapy

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ALLERGIC REACTION; ANOREXIA; ANTICONVULSANT THERAPY; APPETITE; ATAXIA; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CHILDHOOD DISEASE; COGNITIVE DEFECT; DEPRESSION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOCAL EPILEPSY; HUMAN; IRRITABILITY; LIVER TOXICITY; METABOLIC ACIDOSIS; MONOTHERAPY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; PARESTHESIA; PSYCHOSIS; QUALITY OF LIFE; RASH; RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TONIC CLONIC SEIZURE; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ANTICONVULSANTS; BENZODIAZEPINES; CHILD; EPILEPSIES, MYOCLONIC; HUMANS;

EID: 84878857382     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.800045     Document Type: Review

References (55)

1. Leppik IE. Classification of the myoclonic epilepsies. Epilepsia 2003;44:2-6
2. Striano P, Zara F. Pathophysiology of myoclonic seizures. In: Panayiotopoulos CP, editor. Atlas of epilepsy. Springer Science+Business Media, Part 5, London; 2010. p. 235-42
3. Cross E. Treatment of myoclonic epilepsies. Neurol Asia 2004;9:28-9
4. Dulac O, Steru D, Rey E, et al. Sodium valproate monotherapy in childhood epilepsy. Brain Dev 1986;8:47-52
5. Sundqvist A, Tomson T, Lundkvist B. Valproate as monotherapy for juvenile myoclonic epilepsy: dose-effect study. Ther Drug Monit 1998;20:149-57
6. Atakli D, Sozuer D, Atay T, et al. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure 1998;7:63-6
7. Kleveland G, Engelsen BA. Juvenile myoclonic epilepsy: clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure 1998;7:31-8
8. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;2:S8-11
9. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693-720
10. Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010;2010:479364
11. Wlodarczyk BJ, Palacios AM, George TM, Finnell RH. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A 2012;158A:2071-90
12. Striano P, Striano S. New and investigational antiepileptic drugs. Expert Opin Investig Drugs 2009;18:1875-84
13. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008;118:69-86
14. Mikkelsen B, Birket-Smith E, Bradt S, et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch Neurol 1976;33:322-5
15. Obeso JA. Therapy of myoclonus. Clin Neurosci 1995-1996;3:253-7
16. Yamatogi Y, Ohtahara S, Shigematsu H, et al. Single blind comparative study of clobazam with clonazepam in intractable childhood epilepsies. J Jpn Epilepsy Soc 1997;15:110-21
17. Farrell K. Benzodiazepines in the treatment of children with epilepsy. Epilepsia 1986;27:S45-51
18. Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65:1737-43
19. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51
20. Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005;46:161-8
21. Prasad A, Kuzniecky RI, Knowlton RC, et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003;60:1100-5
22. Morris G, Hammer A, Kustra R, Messenheimer J. Lamotrigine for patients with JME following prior treatment with valproate: results of an open-label study. Epilepsy Behavior 2004;5:509-12
23. Genton P, Gelisse P, Crespel A. Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. Epilepsia 2006;47:2083-5
24. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12
25. Striano P, Striano S, Minetti C, Zara F. Refractory, life-threatening status epilepticus in a 3-year-old girl. Lancet Neurol 2008;7:278-84
26. Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005;65:762-4
27. Choi H, Morrell MJ. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin Pharmacother 2003;4(2):243-51
28. Verrotti A, D'Adamo E, Parisi P, et al. Levetiracetam in childhood epilepsy. Paediatr Drugs 2010;12:177-86
29. Noachtar S, Andermann E, Meyvisch P, N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-16
30. Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007;69:1751-60
31. Labate A, Colosimo E, Gambardella A, et al. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006;15:214-18
32. Specchio LM, Gambardella A, Giallonardo AT, et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 2006;71:32-9
33. Belcastro V, Costa C, Galletti F, et al. Rapid effect of levetiracetam in a case of juvenile myoclonic epilepsy. Epilepsy Beh 2009;14:269-70
34. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996;25:225-30
35. Striano P, Sofia V, Capovilla G, et al. A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). Epilepsia 2008;49:425-30
36. Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007;69:250-4
37. Specchio N, Balestri M, Striano P, et al. Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Epilepsy Res 2010;88:112-17
38. Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 2005;20:1610-14
39. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90
40. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-7
41. Arroyo S, Dodson WE, Privitera MD, et al. Randomized dose controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005;112:214-22
42. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004;75:75-9
43. Puri V, Ness S, Sattaluri SJ, et al. Long-term open-label study of adjunctive topiramate in infants with refractory partial-onset seizures. J Child Neurol 2011;10:1271-83
44. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 2002;17:87-96
45. Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6:267-70
46. Vossler D, Conry J, Murphy J, et al. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008;10:31-4
47. Italiano D, Pezzella M, Coppola A, et al. A pilot open-label trial of zonisamide in Unverricht-Lundborg disease. Mov Disord 2011;26:341-3
48. Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Epilepsy Res 2009;83:112-16
49. Tan HJ, Martland TR, Appleton RE, Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure 2010;19:31-5
50. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9
51. Genton P, McMenamin J. Aggravation of seizures by antiepileptic drugs: what to do in clinical practice. Epilepsia 1998;39:S26-9
52. Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003;44:s27-37
53. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:175
54. Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2001;56:1424-5
55. Capovilla G, Beccaria F, Veggiotti P, et al. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol 1999;14:395-400